Cargando…
Olaratumab’s failure in soft tissue sarcoma
Soft tissue sarcomas remain one of the rarest malignancies with numerous subtypes that go undiagnosed. The PDGFRα antagonist Olaratumab (Lartruvo) was withdrawn from the market due to disappointing findings in the phase III studies. We share our experience with this medication in a tertiary care cen...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293854/ https://www.ncbi.nlm.nih.gov/pubmed/34349891 http://dx.doi.org/10.1177/20363613211034115 |
_version_ | 1783725130402234368 |
---|---|
author | Bou Zerdan, Maroun Bidikian, Aram H Alameh, Ibrahim Nakib, Clara El Assi, Hazem I |
author_facet | Bou Zerdan, Maroun Bidikian, Aram H Alameh, Ibrahim Nakib, Clara El Assi, Hazem I |
author_sort | Bou Zerdan, Maroun |
collection | PubMed |
description | Soft tissue sarcomas remain one of the rarest malignancies with numerous subtypes that go undiagnosed. The PDGFRα antagonist Olaratumab (Lartruvo) was withdrawn from the market due to disappointing findings in the phase III studies. We share our experience with this medication in a tertiary care center in the Middle East and North Africa region. Monitor the effect of Olaratumab on sarcomas when it was used prior to its withdrawal, and compare our findings with the literature. We performed a retrospective analysis of adult patients with advanced-/metastatic soft tissue sarcomas treated with at least two cycles of Olaratumab at a tertiary care center in Lebanon during the period from January 1, 2017 to December 31, 2018. Fifteen patients were included in the study. The mean age was 49 with a range of 26–75 years. The median duration of the use of Olaratumab was 21.3 months with a range of 7.3–37 months. The average number of number of cycles received per patient was four. Five patients were deceased. Median PFS was 7.87 months (95% CI 5.28–10.45), and mean OS was 12.26 months (95% CI 8.47–16.05) Median OS was 9.8 months (95% CI 6.07–13.53). Olaratumab has been withdrawn from the market, and it is currently being investigated as part of the phase II ANNOUNCE 2 trial. Our experience from a tertiary care center shows results similar to those reported in the literature. The immunogenicity and heterogeneity of soft tissue sarcomas pose a challenge to the treatment of soft tissue sarcomas, but they also allow a wide array of possible management solutions. |
format | Online Article Text |
id | pubmed-8293854 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-82938542021-08-03 Olaratumab’s failure in soft tissue sarcoma Bou Zerdan, Maroun Bidikian, Aram H Alameh, Ibrahim Nakib, Clara El Assi, Hazem I Rare Tumors Original Research Soft tissue sarcomas remain one of the rarest malignancies with numerous subtypes that go undiagnosed. The PDGFRα antagonist Olaratumab (Lartruvo) was withdrawn from the market due to disappointing findings in the phase III studies. We share our experience with this medication in a tertiary care center in the Middle East and North Africa region. Monitor the effect of Olaratumab on sarcomas when it was used prior to its withdrawal, and compare our findings with the literature. We performed a retrospective analysis of adult patients with advanced-/metastatic soft tissue sarcomas treated with at least two cycles of Olaratumab at a tertiary care center in Lebanon during the period from January 1, 2017 to December 31, 2018. Fifteen patients were included in the study. The mean age was 49 with a range of 26–75 years. The median duration of the use of Olaratumab was 21.3 months with a range of 7.3–37 months. The average number of number of cycles received per patient was four. Five patients were deceased. Median PFS was 7.87 months (95% CI 5.28–10.45), and mean OS was 12.26 months (95% CI 8.47–16.05) Median OS was 9.8 months (95% CI 6.07–13.53). Olaratumab has been withdrawn from the market, and it is currently being investigated as part of the phase II ANNOUNCE 2 trial. Our experience from a tertiary care center shows results similar to those reported in the literature. The immunogenicity and heterogeneity of soft tissue sarcomas pose a challenge to the treatment of soft tissue sarcomas, but they also allow a wide array of possible management solutions. SAGE Publications 2021-07-18 /pmc/articles/PMC8293854/ /pubmed/34349891 http://dx.doi.org/10.1177/20363613211034115 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Bou Zerdan, Maroun Bidikian, Aram H Alameh, Ibrahim Nakib, Clara El Assi, Hazem I Olaratumab’s failure in soft tissue sarcoma |
title | Olaratumab’s failure in soft tissue sarcoma |
title_full | Olaratumab’s failure in soft tissue sarcoma |
title_fullStr | Olaratumab’s failure in soft tissue sarcoma |
title_full_unstemmed | Olaratumab’s failure in soft tissue sarcoma |
title_short | Olaratumab’s failure in soft tissue sarcoma |
title_sort | olaratumab’s failure in soft tissue sarcoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293854/ https://www.ncbi.nlm.nih.gov/pubmed/34349891 http://dx.doi.org/10.1177/20363613211034115 |
work_keys_str_mv | AT bouzerdanmaroun olaratumabsfailureinsofttissuesarcoma AT bidikianaramh olaratumabsfailureinsofttissuesarcoma AT alamehibrahim olaratumabsfailureinsofttissuesarcoma AT nakibclarael olaratumabsfailureinsofttissuesarcoma AT assihazemi olaratumabsfailureinsofttissuesarcoma |